Ciancia Silvia, Dubois Vanessa, Craen Margarita, Klink Daniel, Verroken Charlotte, Vanderschueren Dirk, Cools Martine
Department of Internal Medicine and Pediatrics, Ghent University, Ghent, Belgium.
Clinical and Experimental Endocrinology, Department of Chronic Diseases and Metabolism (Chrometa), KU Leuven, Leuven, Belgium.
Int J Transgend Health. 2024 May 16;26(3):861-873. doi: 10.1080/26895269.2024.2353224. eCollection 2025.
The effects of puberty suppression for more than 2 years before the start of gender-affirming hormones (GAH) on bone mass acquisition and body composition are understudied.
Retrospective study on 46 transgender adolescents (20 trans boys and 26 trans girls) receiving a gonadotropin-releasing hormone analogue (GnRHa) from Tanner stage 2-3, followed by GAH around the age of 16 years. At start of GnRHa and at start of GAH, dual-energy X-ray absorptiometry (DXA) at lumbar spine (LS), femoral neck (FN) and total body (TB), handgrip strength test and fasting blood sampling were performed. Z-scores were calculated using reference values for both cis girls and cis boys.
GnRHa were administered for a median of 3.2 years (± 0.69) in trans boys and 2.7 years (± 1.05) in trans girls. Bone mineral apparent density (BMAD)-LS Z-scores decreased significantly in both trans boys and trans girls, while BMAD-FN Z-scores decreased only in trans boys. Fat% and Fat Mass Index Z-scores significantly increased in both groups, while Lean Mass Index Z-scores significantly decreased. Handgrip strength Z-scores for the sex registered at birth (SRAB) remained stable in trans boys while they decreased in trans girls. There was no significant influence of the treatment on either insulin sensitivity or lipid profile.
GnRHa administration for more than two years during the physiological time of puberty decreases bone mass acquisition, mainly at the lumbar spine and induces a general increase in fat mass. Although lean mass acquisition is undermined in both groups, handgrip strength is affected mainly in trans girls compared with age-matched peers for the SRAB.
在开始使用性别确认激素(GAH)之前,超过2年的青春期抑制对骨量获取和身体成分的影响尚未得到充分研究。
对46名跨性别青少年(20名跨性别男孩和26名跨性别女孩)进行回顾性研究,这些青少年从坦纳2 - 3期开始接受促性腺激素释放激素类似物(GnRHa)治疗,随后在16岁左右开始使用GAH。在开始使用GnRHa时和开始使用GAH时,对腰椎(LS)、股骨颈(FN)和全身(TB)进行双能X线吸收测定(DXA),进行握力测试并采集空腹血样。使用顺性别女孩和顺性别男孩的参考值计算Z分数。
跨性别男孩使用GnRHa的中位时间为3.2年(±0.69),跨性别女孩为2.7年(±1.05)。跨性别男孩和跨性别女孩的骨矿物质表观密度(BMAD)-LS Z分数均显著下降,而BMAD-FN Z分数仅在跨性别男孩中下降。两组的脂肪百分比和脂肪质量指数Z分数均显著增加,而瘦体重指数Z分数显著下降。跨性别男孩中,出生时登记的性别(SRAB)的握力Z分数保持稳定,而跨性别女孩中则下降。该治疗对胰岛素敏感性或血脂谱均无显著影响。
在青春期生理阶段使用GnRHa超过两年会减少骨量获取,主要是在腰椎,并导致脂肪量普遍增加。尽管两组的瘦体重获取均受到影响,但与SRAB的年龄匹配同龄人相比,握力主要在跨性别女孩中受到影响。